ConCallIQ
Go Pro
Home › Glenmark Pharmaceuticals › Revenue History

Glenmark Pharmaceuticals Revenue History — Quarter by Quarter

Glenmark Pharmaceuticals's revenue moved from ₹3,264 Cr in Q1 FY26 to ₹3,901 Cr in Q3 FY26, a 19.5% change over 3 quarters. The table keeps each quarter linked back to the underlying earnings page.

Revenue by Quarter

QuarterRevenue (₹ Cr)YoY Change
Q3 FY26₹3,901 Cr+15.1%
Q2 FY26₹6,047 Cr+76%
Q1 FY26₹3,264 Cr+0.6%

What management said about revenue

G

Q3 FY26 · Flovent 44 mcg ANDA approval expected in Q4

Management expects USFDA approval for generic Flovent 44 mcg in Q4 FY26, which could drive US growth.

G

Q2 FY26 · India business run-rate of ₹1,150-1,200 crore from Q3 FY26

Management expects India formulation sales to normalize to ₹1,150-1,200 crore per quarter starting Q3 FY26, with FY27 revenue exceeding ₹4,800 crore.

G

Q2 FY26 · FY27 consolidated revenue target of ₹17,000-18,000 crore

Management guided FY27 topline between ₹17,000-18,000 crore, implying ~15% growth over FY26 estimated run-rate.

G

Q1 FY26 · India business to grow 10-15% CAGR over 3-5 years

Management expects India business to grow at 10-15% CAGR over the next 3-5 years, with secondary and reported growth converging from Q3.

G

Q1 FY26 · Europe and emerging markets to return to double-digit growth in FY26

Europe region expected to return to double-digit growth from Q2 onwards, and emerging markets anticipated to grow double-digit on constant currency basis in FY26.